Topoisomerases in human leukemia.
Peereboom
D
D
Oncology Center, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.
Charron
M
M
Kaufmann
S H
SH
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002166:Camptothecin / Q000627:therapeutic use; D004264:DNA Topoisomerases, Type I / Q000502:physiology; D004250:DNA Topoisomerases, Type II / Q000502:physiology; D019008:Drug Resistance, Neoplasm; D006413:Hematopoietic System / Q000503:physiopathology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; D002166:Camptothecin